间充质干细胞源性外泌体对前部缺血性视神经病变患者的治疗潜力  

Therapeutic potential of mesenchymal stem cells-exosomes for anterior ischemic optic neuropathy

作　　者：李东丽 宫媛媛[1] LI Dongli;GONG Yuanyuan(Department of Ophthalmology,Shanghai General Hospital,Shanghai Jiaotong University,School of Medicine,Shanghai 200080,China)

机构地区：[1]上海交通大学附属第一人民医院眼科,上海市200080

出　　处：《眼科新进展》2020年第5期492-496,共5页Recent Advances in Ophthalmology

基　　金：国家重点研发计划资助(编号2016YFC0904800);上海市第一人民医院临床研究创新团队建设项目资助(编号CTCCR-2018BP04);上海市科学技术委员会科研计划项目(编号19401932700)。

摘　　要：前部缺血性视神经病变(anterior ischemic optic neuropathy,AION)是继青光眼后成人永久性视神经相关视力丧失的第二大常见原因,目前尚无确切有效的治疗方案。既往研究发现间充质干细胞源性外泌体(mesenchymal stem cells-exosomes,MSC-exosomes)与MSCs非常相似地改善缺血后神经组织的损伤,并诱导与增强血管神经发生相关的长期神经保护作用。外泌体是细胞-细胞间交流的一种重要通讯途径,因此可作为小分子物质传递载体信号,并通过不同机制作用于靶细胞,从而成为眼前部缺血性视神经病变潜在的有效治疗工具。本文对MSC-exosomes的生物发生及其功能,以及MSC-exosomes在前部缺血性视神经性病变中的治疗机制进行综述。Anterior ischemic optic neuropathy(AION)is the second most common cause of permanent vision loss after glaucoma.There is no actual and effective treatment plan.Mesenchymal stem cells-exosomes(MSC-exosomes)have been shown to significantly attenuate post-ischemic neuronal damage and induce long-term neuroprotection associated with enhanced angiogenesis of MSCs.Exosomes are an important communication pathway for cell-cell communication,and can be used as a small molecule to transmit carrier signals and act on the target cells by different mechanisms.Therefore,MSC-exosomes are expected to be an effective therapeutic tool for the treatment of AION.This article reviews the biogenesis and physiological functions of MSC-exosomes,and their therapeutic mechanism for AION.

关 键 词：外泌体 前部缺血性视神经病变 间充质干细胞 

分 类 号：R774.6[医药卫生—眼科]